Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 17;4(10):711-720.
doi: 10.1016/j.jacasi.2024.07.012. eCollection 2024 Oct.

Translational Research and Clinical Application of Traditional Chinese Medicine in Cardiovascular Diseases

Iokfai Cheang  1 , Ziqi Chen  1 , Xu Zhu  1 , Tongxin Wang  2 , Liping Chang  2 , Rongrong Gao  1 , Zhenhua Jia  2 , Xinli Li  1
Affiliations
Review

Translational Research and Clinical Application of Traditional Chinese Medicine in Cardiovascular Diseases

Iokfai Cheang et al. JACC Asia. .

Abstract

Luobing theory is based on the principles of traditional Chinese medicine (TCM) and focuses on the regulation of blood circulation. The translation of Luobing theory into clinical practice has shown promising results in the treatment of cardiovascular diseases (CVDs). Studies have reported the benefits of using Luobing theory in the treatment of metabolic syndrome, atherosclerosis, arrhythmia, and heart failure. This review article provides an overview of the evidence-based application of TCM Luobing theory in the treatment of CVDs. It also highlights the challenges and opportunities of translating TCM into clinical practice and provides valuable insights for future CVD research.

Keywords: Qiliqiangxin capsule; Tongxinluo capsule; cardiovascular continuum; cardiovascular disease; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

This work was supported by the State Key Laboratory for Innovation and Transformation of Luobing Theory, the General Program of National Natural Science Foundation of China (82370389, 81970339, Dr Li; 82200425, Dr Gao), the National High Technology Research and Development Program of China (2017YFC1700505, Dr Li), the Excellent Young Scientists Fund of Jiangsu (BK20231538, Dr Gao), and the Qing Lan Project of Jiangsu (Dr Gao). Dr Li is an Associate Fellow at the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine. Drs Zhu and Cheang are post-doctorate Follows at Nanjing Medical University. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Central Illustration
Central Illustration
Progression and Interventions With Traditional Chinese Medicine of Cardiovascular Diseases The graphic outlines the progression from risk factors to heart failure in cardiovascular diseases (CVDs) and the intervention points of traditional Chinese medicines (TCM). Downward arrows represent progression of CVD, and yellow circles indicate disease stages based on TCM. The TCMs used include Jinlida (JLD), Tongxinluo (TXL), Shensongyangxin (SSYX), and Qiliqiangxin (QLQX) target-specific stages to mitigate disease progression, marked in brown square. Light blue squares represent the evidence-based trial conducted in the recent years include: FOCUS (Interventional study of Jinlida treatment for abnormal glucose metabolism in metabolic syndrome), TXL-CAP (A randomized, double-blind, placebo parallel controlled, multi-center clinical study of Tongxinluo capsule in the treatment of acute coronary syndrome with atherosclerotic plaque), CTS-AMI (China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction), SS-AFRF (Shensongyangxin Capsule Regulates Persistent Atrial Fibrillation After Radiofrequency Catheter Ablation), and QUEST (Qiliqiangxin in Heart Failure: Assessment of Reduction in Mortality).
See this image and copyright information in PMC

References

    1. Hao P., Jiang F., Cheng J., Ma L., Zhang Y., Zhao Y. Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol. 2017;69(24):2952–2966. doi: 10.1016/j.jacc.2017.04.041. - DOI - PubMed
    1. Curran J. The Yellow Emperor’s Classic of Internal Medicine. Br Med J. 2008;336:777. doi: 10.1136/bmj.39527.472303.4E. - DOI
    1. Wu Y. Construction of the vessel-collateral theory and its guidance for prevention and treatment of vasculopathy. Front Med. 2011;5(2):118–122. doi: 10.1007/s11684-011-0140-z. - DOI - PubMed
    1. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 pt 1):1244–1263. doi: 10.1016/0002-8703(91)90694-d. - DOI - PubMed
    1. Visseren F.L.J., Mach F., Smulders Y.M., et al. ESC National Cardiac Societies ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484. - DOI - PubMed

LinkOut - more resources